GARDP will work largely as a virtual R&D initiative through direct partnerships and multi-stakeholder collaborations, including with academia, industry, international organizations and governments. Working with patented and non-patented drug candidates, GARDP will follow DNDi’s access-driven intellectual property policy in its agreements. While maintaining a clear focus and strategy for all its programmatic interventions,
GARDP will develop partnership models tailored to the capacity and ability of actors involved: in certain programmes, GARDP will need to be actively driving and implementing R&D programmes, while in others, equitable partnerships will be sought whereby GARDP brings in the appropriate amount of funding, direction, and support. All GARDP funding will be linked to the need to develop and make available affordable products that answer to public health needs.